| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.3 |
| mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.057 | 0.3 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.3 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | 0.053 | 0.3 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | Ispinesib Mesylate | GDSC1000 | pan-cancer | AAC | -0.033 | 0.3 |
| mRNA | XMD8-92 | GDSC1000 | pan-cancer | AAC | 0.049 | 0.3 |